A population-based study of prostate cancer chemotherapy

V Harris; K Lloyd; S Forsey; P Rogers; M Roche; C Parker

doi:10.1016/j.clon.2011.04.014

A population-based study of prostate cancer chemotherapy

Clin Oncol (R Coll Radiol). 2011 Dec;23(10):706-8. doi: 10.1016/j.clon.2011.04.014. Epub 2011 May 23.

Authors

V Harris¹, K Lloyd, S Forsey, P Rogers, M Roche, C Parker

Affiliation

¹ Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK. victoria.harris@rmh.nhs.uk

PMID: 21602036
DOI: 10.1016/j.clon.2011.04.014

Abstract

The use of chemotherapy in the treatment of prostate cancer is a relatively recent development, with no published data on the patterns of care in the UK. We carried out a population-based study to assess variation in the use of prostate cancer chemotherapy over time in a UK cancer network.

MeSH terms

Antineoplastic Agents / therapeutic use*
Docetaxel
Drug Therapy / statistics & numerical data
Drug Therapy / trends
Epirubicin / therapeutic use
Humans
Male
Mitoxantrone / therapeutic use
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / mortality
Prostatic Neoplasms / therapy
Taxoids / therapeutic use
United Kingdom / epidemiology

Substances

Antineoplastic Agents
Taxoids
Docetaxel
Epirubicin
Mitoxantrone